Keiran S M Smalley

List of Publications by Year in Descending Order

162 papers	13,728 citations	54 h-index	115 g-index
192 ext. papers	15,463 ext. citations	7.7 avg, IF	6.17 L-index

#	Paper	IF	Citations
162	MEK-ing the Most of It: Strategies to Co-target GEF and MAPK in Uveal Melanoma. *Clinical Cancer Research*, **2021**, 27, 1217-1219	12.9	3
161	Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. *Cancer Immunology Research*, **2021**, 9, 554-567	12.5	3
160	A Mutational Survey of Acral Nevi. *JAMA Dermatology*, **2021**, 157, 831-835	5.1	1
159	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. *Clinical Cancer Research*, **2021**, 27, 4109-4125	12.9	14
158	Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor-Resistant Melanoma. *Journal of Investigative Dermatology*, **2021**, 141, 840-851.e4	4.3	7
157	A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. *Journal of Visualized Experiments*, **2021**,	1.6	2
156	Melanoma brain metastases: Biological basis and novel therapeutic strategies. *Experimental Dermatology*, **2021**,	4	1
155	Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma. *Journal of Investigative Dermatology*, **2021**,	4.3	2
154	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. *Pigment Cell and Melanoma Research*, **2020**, 33, 527-541	4.5	21
153	Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses. *Cancer Discovery*, **2020**, 10, 176-178	24.4	5
152	Translational pathology, genomics and the development of systemic therapies for acral melanoma. *Seminars in Cancer Biology*, **2020**, 61, 149-157	12.7	7
151	Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance. *Clinical Cancer Research*, **2020**, 26, 2163-2175	12.9	19
150	Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell and Melanoma Research*, **2020**, 33, 507-514	4.5	13
149	HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clinical Cancer Research*, **2019**, 25, 5686-5701	12.9	42
148	K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. *Nature Communications*, **2019**, 10, 1870	17.4	26
147	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. *Cancer Research*, **2019**, 79, 2947-2961	10.1	37
146	MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. *Cancer Research*, **2019**, 79, 5812-5825	10.1	3

145	Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. *EBioMedicine*, **2019**, 48, 178-190	8.8	28
144	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. *Pigment Cell and Melanoma Research*, **2019**, 32, 458-469	4.5	15
143	Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology. *Survey of Ophthalmology*, **2019**, 64, 272-288	6.1	17
142	ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC). *Pharmacological Research*, **2019**, 141, 63-72	10.2	9
141	Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma. *Clinical Cancer Research*, **2018**, 24, 5516-5524	12.9	37
140	ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?. *Cancer Discovery*, **2018**, 8, 140-142	24.4	30
139	Get with the Program! Stemness and Reprogramming in Melanoma Metastasis. *Journal of Investigative Dermatology*, **2018**, 138, 10-13	4.3	4
138	The biology and therapeutic management of melanoma brain metastases. *Biochemical Pharmacology*, **2018**, 153, 35-45	6	7
137	Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. *Cancer*, **2018**, 124, 2254-2255	6.4	
136	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. *Cancer*, **2018**, 124, 297-305	6.4	59
135	Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. *Molecular Oncology*, **2018**, 12, 74-88	7.9	15
134	Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines. *Molecular Cancer Therapeutics*, **2018**, 17, 73-83	6.1	12
133	EXTH-39. DETECTION, MOLECULAR PROFILING AND CULTURE OF CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) IN MELANOMA TO IMPROVE DIAGNOSIS AND TREATMENT STRATEGIES. *Neuro-Oncology*, **2018**, 20, vi93-vi93	1	1
132	Frontiers in pigment cell and melanoma research. *Pigment Cell and Melanoma Research*, **2018**, 31, 728-735	4.5	8
131	Why do women with melanoma do better than men?. *ELife*, **2018**, 7,	8.9	14
130	Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. *Pharmacological Research*, **2017**, 119, 242-250	10.2	15
129	SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. *Bioinformatics*, **2017**, 33, 2951-2953	7.2	7
128	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. *Clinical Cancer Research*, **2017**, 23, 6203-6214	12.9	22

127	Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. *Melanoma Research*, **2017**, 27, 545-557	3.3	4
126	BRAF-MEK inhibition in melanoma brain metastases: a new hope. *Lancet Oncology, The*, **2017**, 18, 836-837	31.7	3
125	Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. *Oncogene*, **2017**, 36, 1849-1861	9.2	54
124	Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies. *Cancer Control*, **2017**, 24, 42-46	2.2	8
123	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. *Oncogene*, **2016**, 35, 1225-35	9.2	56
122	Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. *Journal of Proteome Research*, **2016**, 15, 4476-4489	5.6	13
121	A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. *Melanoma Research*, **2016**, 26, 481-6	3.3	5
120	The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. *Biochemical Pharmacology*, **2016**, 122, 1-9	6	25
119	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
118	Essential role of HDAC6 in the regulation of PD-L1 in melanoma. *Molecular Oncology*, **2016**, 10, 735-750	7.9	89
117	Combination Therapies for Melanoma: A New Standard of Care?. *American Journal of Clinical Dermatology*, **2016**, 17, 99-105	7.1	15
116	Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.. *Journal of Clinical Oncology*, **2016**, 34, 9544-9544	2.2	2
115	BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. *Melanoma Research*, **2016**, 26, 83-7	3.3	18
114	Improving patient outcomes to targeted therapies in melanoma. *Expert Review of Anticancer Therapy*, **2016**, 16, 633-41	3.5	5
113	Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. *European Journal of Cancer*, **2016**, 67, 213-222	7.5	23
112	Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. *International Journal of Cancer*, **2016**, 139, 1195-201	7.5	28
111	The state of melanoma: challenges and opportunities. *Pigment Cell and Melanoma Research*, **2016**, 29, 404-16	4.5	63
110	Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. *Cancer Discovery*, **2015**, 5, 264-73	24.4	61

109	Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. *Methods*, **2015**, 81, 41-9	4.6	9
108	Inhibition of BRAF and MEK in BRAF-mutant melanoma. *Lancet, The*, **2015**, 386, 410-2	40	7
107	The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. *Molecular Cancer Therapeutics*, **2015**, 14, 1354-64	6.1	23
106	BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. *Journal of Investigative Dermatology*, **2015**, 135, 3115-3124	4.3	61
105	XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. *Journal of Investigative Dermatology*, **2015**, 135, 2542-2544	4.3	9
104	Beyond BRAF: where next for melanoma therapy?. *British Journal of Cancer*, **2015**, 112, 217-26	8.7	87
103	Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. *Experimental Dermatology*, **2015**, 24, 657-8	4	7
102	Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. *Proteomics*, **2015**, 15, 327-39	4.8	12
101	Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. *Molecular Oncology*, **2015**, 9, 1447-1457	7.9	82
100	Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma. *Molecular and Cellular Oncology*, **2015**, 2, e1008291	1.2	3
99	The complexity of microenvironment-mediated drug resistance. *Genes and Cancer*, **2015**, 6, 367-8	2.9	11
98	Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy. *Cancer Drug Discovery and Development*, **2015**, 137-162	0.3	
97	Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. *Tissue Engineering - Part A*, **2014**, 20, 2412-21	3.9	32
96	Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. *Molecular Cancer Therapeutics*, **2014**, 13, 2793-2804	6.1	70
95	Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. *Biochemical Pharmacology*, **2014**, 91, 417-25	6	8
94	Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. *Clinical Cancer Research*, **2014**, 20, 4186-92	12.9	49
93	Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. *Molecular and Cellular Proteomics*, **2014**, 13, 1844-54	7.6	44
92	Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. *Pigment Cell and Melanoma Research*, **2014**, 27, 465-78	4.5	43

91	Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. *Melanoma Research*, **2014**, 24, 448-53	3.3	10
90	Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. *Pigment Cell and Melanoma Research*, **2014**, 27, 1154-8	4.5	40
89	Resistance to Raf inhibition in cancer. *Drug Discovery Today: Technologies*, **2014**, 11, 27-32	7.1	24
88	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. *Journal of Clinical Oncology*, **2014**, 32, 9062-9062	2.2	
87	Fibroblast-mediated drug resistance in cancer. *Biochemical Pharmacology*, **2013**, 85, 1033-41	6	105
86	Melanoma genotypes and phenotypes get personal. *Laboratory Investigation*, **2013**, 93, 858-67	5.9	16
85	Mutant BRAF: a novel mediator of microenvironmental escape in melanoma?. *Journal of Investigative Dermatology*, **2013**, 133, 1135-7	4.3	1
84	In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. *Molecular Pharmaceutics*, **2013**, 10, 3175-85	5.6	10
83	Targeted therapy in melanoma. *Clinics in Dermatology*, **2013**, 31, 200-8	3	19
82	Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. *Nature Reviews Clinical Oncology*, **2013**, 10, 390-9	19.4	140
81	Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach. *Cancer Research*, **2013**, 73, 6874-85	10.1	35
80	Targeted therapy for melanoma: is double hitting a home run?. *Nature Reviews Clinical Oncology*, **2013**, 10, 5-6	19.4	10
79	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. *Oncogene*, **2013**, 32, 3009-18	9.2	99
78	Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. *Molecular Cancer Therapeutics*, **2013**, 12, 901-12	6.1	43
77	Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. *Clinical Cancer Research*, **2013**, 19, 6329-30	12.9	20
76	Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. *Science Signaling*, **2013**, 6, ra7	8.8	96
75	An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance. *Cancer Discovery*, **2013**, 3, 260-3	24.4	30
74	Novel treatments for melanoma brain metastases. *Cancer Control*, **2013**, 20, 298-306	2.2	12

73	The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. *PLoS ONE*, **2013**, 8, e59588	3.7	48
72	The current state of targeted therapy in melanoma: this time it's personal. *Seminars in Oncology*, **2012**, 39, 204-14	5.5	22
71	GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. *Journal of Investigative Dermatology*, **2012**, 132, 2818-27	4.3	30
70	The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. *Clinical Cancer Research*, **2012**, 18, 2502-14	12.9	130
69	A brief history of melanoma: from mummies to mutations. *Melanoma Research*, **2012**, 22, 114-22	3.3	73
68	Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. *Cancer Journal (Sudbury, Mass.)*, **2012**, 18, 124-31	2.2	60
67	Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance. *Cancer Discovery*, **2012**, 2, 390-2	24.4	9
66	Melanoma and Other Skin Cancers **2012**, 439-468		
65	Fibroblasts contribute to melanoma tumor growth and drug resistance. *Molecular Pharmaceutics*, **2011**, 8, 2039-49	5.6	90
64	Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. *Biochemical Pharmacology*, **2011**, 82, 201-9	6	136
63	A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. *Proteomics - Clinical Applications*, **2011**, 5, 383-96	3.1	43
62	PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. *Cancer Research*, **2011**, 71, 2750-60	10.1	419
61	Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis?. *Expert Review of Anticancer Therapy*, **2011**, 11, 711-4	3.5	15
60	Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. *Oncotarget*, **2011**, 2, 329-35	3.3	17
59	Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. *British Journal of Cancer*, **2010**, 102, 1724-30	8.7	242
58	Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines. *Methods in Enzymology*, **2010**, 484, 549-67	1.7	10
57	Understanding melanoma signaling networks as the basis for molecular targeted therapy. *Journal of Investigative Dermatology*, **2010**, 130, 28-37	4.3	98
56	PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. *Pigment Cell and Melanoma Research*, **2010**, 23, 820-7	4.5	122

55	Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. *Biochemical Pharmacology*, **2010**, 80, 739-47	6	15
54	PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. *Current Opinion in Investigational Drugs*, **2010**, 11, 699-706		38
53	The future of targeted therapy approaches in melanoma. *Expert Opinion on Drug Discovery*, **2009**, 4, 445-66	6.6	1
52	Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. *Cancer Research*, **2009**, 69, 3241-4	10.1	60
51	Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. *Future Oncology*, **2009**, 5, 775-8	3.6	17
50	Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. *International Journal of Cancer*, **2009**, 124, 1245-50	7.5	14
49	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. *Oncogene*, **2009**, 28, 85-94	9.2	170
48	Integrating BRAF/MEK inhibitors into combination therapy for melanoma. *British Journal of Cancer*, **2009**, 100, 431-5	8.7	73
47	Melanoma Biomarkers. *Molecular Diagnosis and Therapy*, **2009**, 13, 283-296	4.5	29
46	Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report. *Pigment Cell and Melanoma Research*, **2009**, 22, 386-7	4.5	10
45	Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. *Pigment Cell and Melanoma Research*, **2009**, 22, 529-31	4.5	8
44	c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. *Histology and Histopathology*, **2009**, 24, 643-50	1.4	54
43	Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. *Molecular Diagnosis and Therapy*, **2009**, 13, 283-96	4.5	11
42	The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. *Gastroenterology*, **2008**, 134, 1981-93	13.3	96
41	Somatic genetics and targeted therapies for cutaneous melanoma. *Update on Cancer Therapeutics*, **2008**, 3, 81-87		
40	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3041-6	11.5	1056
39	Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. *ACS Chemical Biology*, **2008**, 3, 305-16	4.9	49
38	In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. *Expert Opinion on Drug Discovery*, **2008**, 3, 1-10	6.2	83

37	Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. *Molecular Cancer Therapeutics*, **2008**, 7, 1218-26	6.1	16
36	The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. *Clinical Cancer Research*, **2008**, 14, 230-9	12.9	197
35	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. *Molecular Cancer Therapeutics*, **2008**, 7, 2876-83	6.1	246
34	Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. *Cancer Research*, **2008**, 68, 5743-52	10.1	79
33	Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. *Molecular Cancer Therapeutics*, **2008**, 7, 2866-75	6.1	58
32	Similar biological activities of two isostructural ruthenium and osmium complexes. *Chemistry - A European Journal*, **2008**, 14, 4816-22	4.8	81
31	Therapeutic Targeting of the Melanoma Stem Cell Population. *Translational Medicine Series*, **2008**, 83-98		
30	Targeting BRAF Activity as a NovelParadigm for Melanoma Therapy. *Translational Medicine Series*, **2008**, 67-82		
29	Rewired ERK-JNK signaling pathways in melanoma. *Cancer Cell*, **2007**, 11, 447-60	24.3	240
28	Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. *British Journal of Cancer*, **2007**, 96, 445-9	8.7	78
27	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. *Expert Review of Dermatology* , **2007**, 2, 179-190		
26	Is ERK activation a good biomarker for estradiol and tamoxifen effects?. *Cancer Biology and Therapy* , **2007**, 6, 119-20	4.6	1
25	An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. *Cancer Research*, **2007**, 67, 209-17	10.1	207
24	Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. *American Journal of Pathology*, **2007**, 170, 709-21	5.8	106
23	Towards the targeted therapy of melanoma. *Mini-Reviews in Medicinal Chemistry*, **2006**, 6, 387-93	3.2	20
22	Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. *Cancer Research*, **2006**, 66, 4182-90	10.1	228
21	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. *Molecular Cancer Therapeutics*, **2006**, 5, 1136-44	6.1	372
20	Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. *Cancer Research*, **2006**, 66, 11100-5	10.1	229

19	Life isnR flat: taking cancer biology to the next dimension. *In Vitro Cellular and Developmental Biology - Animal*, **2006**, 42, 242-7	2.6	223
18	Defining the conditions for the generation of melanocytes from human embryonic stem cells. *Stem Cells*, **2006**, 24, 1668-77	5.8	95
17	Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. *American Journal of Pathology*, **2005**, 166, 1541-54	5.8	122
16	Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. *Annals of the New York Academy of Sciences*, **2005**, 1059, 16-25	6.5	68
15	Adhesion, migration and communication in melanocytes and melanoma. *Pigment Cell & Melanoma Research*, **2005**, 18, 150-9		251
14	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. *Seminars in Cancer Biology*, **2005**, 15, 451-9	12.7	48
13	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. *Expert Review of Anticancer Therapy*, **2005**, 5, 1069-78	3.5	17
12	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. *Frontiers in Bioscience - Landmark*, **2005**, 10, 2986-3001	2.8	208
11	Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. *Journal of Investigative Dermatology*, **2004**, 123, xvi-xvii	4.3	10
10	The role of altered cell-cell communication in melanoma progression. *Journal of Molecular Histology* , **2004**, 35, 309-18	3.3	116
9	A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. *International Journal of Cancer*, **2003**, 104, 527-32	7.5	286
8	Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. *International Journal of Cancer*, **2003**, 105, 165-75	7.5	78
7	Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. *International Journal of Cancer*, **2002**, 98, 514-22	7.5	45
6	Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. *Melanoma Research*, **2002**, 12, 187-92	3.3	30
5	The treatment of advanced renal cell cancer with high-dose oral thalidomide. *British Journal of Cancer*, **2001**, 85, 953-8	8.7	89
4	Ligand internalization and recycling by human recombinant somatostatin type 4 (h sst(4)) receptors expressed in CHO-K1 cells. *British Journal of Pharmacology*, **2001**, 132, 1102-10	8.6	15
3	The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. *FEBS Letters*, **2000**, 476, 198-202	3.8	128
2	The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification. *Biochemical and Biophysical Research Communications*, **1999**, 263, 239-43	3.4	31

1	Differential agonist activity of somatostatin and L-362855 at human recombinant sst4 receptors. *British Journal of Pharmacology*, **1998**, 125, 833-41	8.6	21